pharma · Pompe Disease (Late-onset) · Fabry Disease
Pacalis Therapeutics Pty
AMICUS THERAPEUTICS PTY LTD
AMICUS THERAPEUTICS PTY is a pharma organization headquartered in AU. Primary therapeutic focus areas include Pompe Disease (Late-onset), Fabry Disease, Fabry disease. NovaPharmaNews links 5 clinical program(s), 1 drug p
melbourne, AU HQ
2023 Founded
1 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- melbourne, AU
- Founded
- 2023
- Employees
- 1
- Programs
- 5
- Drugs
- 6
- Patents
- 0
AT2221
Phase 3 · small molecule · Pompe Disease (Late-onset)
AT2221 for Pompe Disease (Late-onset) is a Phase 3 program (small_molecule) at AMICUS THERAPEUTICS PTY LTD with 1 ClinicalTrials.gov record(s).
Internal code ATB200-07
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AMICUS THERAPEUTICS PTY LTD
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Pompe Disease (Late-onset)
- Status
- completed
- Trials
- 1